Klaria Pharma Holding AB (FRA:6FN) Dividends Received


FRA:6FN Klaria Pharma Holding AB FRA:6FN
9 GF Score
Price €0.06
GF Value €0.03
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Klaria Pharma Holding AB Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:6FN
9GF Score
Klaria Pharma Holding AB FRA:6FN
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Klaria Pharma Holding AB (FRA:6FN) Overvalued in 2026?

Based on GuruFocus' analysis, Klaria Pharma Holding AB stock appears to be overvalued. The current stock price of €0.06 is trading 115.7% above its estimated GF Value™ of €0.03. GuruFocus considers Klaria Pharma Holding AB to be Significantly Overvalued.

Key valuation signals for FRA:6FN:

  • Dividends Received:
  • GF Value™: €0.03 vs. price of €0.06 (115.7% above fair value)
  • GF Score™: 9/100 with 6 warning signs

No single metric tells the full story. See the FRA:6FN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Klaria Pharma Holding AB Business Description

Other Exchanges KLAR:Sweden
Address Virdings Alle 2, Uppsala, CHE, 754 50
Klaria Pharma Holding AB is a Swedish pharmaceutical company that develops rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Its patented drug delivery platform consists of an alginate-based polymer film that enables the absorption of a product's active substance through the oral mucosa.
9GF Score

Get the complete analysis for FRA:6FN

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.06
Price
€0.03
GF Value